文献速递肿瘤 PET/CT核素与放射性配体治疗

18F-FDG PET/MRI评估软组织肉瘤隔离肢体灌注治疗反应

18F-FDG PET/MRI for Therapy Response Assessment of Isolated Limb Perfusion in Patients with Soft-Tissue Sarcomas.
PubMed 文献 · J Nucl Med · 2019-03-29

该前瞻性研究纳入45例病理证实的软组织肉瘤患者,在隔离肢体灌注前后行18F-FDG PET/MRI,以术后病理Salzer-Kuntschik分级为参考标准评估治疗反应。PERCIST的敏感度85%、特异度78%、准确率82%、AUC 0.82,优于RECIST和Choi标准;联合回归模型AUC 0.90,但与代谢参数差异未达显著(P=0.067)。

要点

  • PERCIST评估隔离肢体灌注治疗反应的AUC为0.82,优于RECIST(0.56)和Choi标准(0.57)。
  • 联合回归模型AUC达0.90,但与单独代谢参数比较差异未达显著(P=0.067)。
  • MRI可提供术前评估信息,PET与MRI联合可能有助于更可靠的治疗计划和监测。

核心结论

  • 18F-FDG PET在评估软组织肉瘤新辅助隔离肢体灌注治疗反应方面优于MRI数据集。
  • 联合18F-FDG PET与MRI可能有助于更可靠的治疗计划和治疗监测。

研究设计与样本

  • 前瞻性纳入45例病理证实的软组织肉瘤患者,在隔离肢体灌注前后行一体化18F-FDG PET/MRI检查。
  • 以术后肿瘤切除标本的Salzer-Kuntschik 6级回归量表病理结果为参考标准,将患者分为反应者(I-III级)和非反应者(IV-VI级)。

主要发现

  • 病理分析将27例归为反应者(I-III级),18例归为非反应者(IV-VI级)。
  • RECIST的敏感度22%、特异度89%、阳性预测值75%、阴性预测值43%、诊断准确率49%,AUC为0.56。
  • Choi标准的敏感度70%、特异度44%、阳性预测值66%、阴性预测值50%、诊断准确率60%,AUC为0.57。
  • PERCIST的敏感度85%、特异度78%、阳性预测值85%、阴性预测值78%、诊断准确率82%,AUC为0.82。
  • 联合回归模型AUC为0.90,高于单独分析,但与代谢参数的差异未达显著(P=0.067)。

关键数值与推荐

  • 治疗反应评估采用RECIST、MR适配的Choi标准和PERCIST。
  • 参考标准为Salzer-Kuntschik 6级回归量表:I-III级为反应者,IV-VI级为非反应者。
  • PERCIST的AUC为0.82,RECIST为0.56,Choi标准为0.57,联合回归模型为0.90。

临床怎么用

  • 在软组织肉瘤隔离肢体灌注治疗反应评估中,可优先考虑18F-FDG PET代谢标准(PERCIST)。
  • MRI仍可提供有价值的术前评估信息,PET与MRI联合可能优化治疗计划和监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Our purpose was to assess the diagnostic potential of simultaneously acquired 18F-FDG PET and MRI data sets for therapy response assessment of isolated limb perfusion (ILP) in patients with soft-tissue sarcomas (STS). Methods: In total, 45 patients with histopathologically verified STS were prospectively enrolled for an integrated 18F-FDG PET/MRI examination before and after ILP. Therapy response was assessed based on different MRI- and PET-derived morphologic (RECIST and the MR-adapted Choi criteria) and metabolic (PERCIST) criteria. In addition, a regression model was used combining relative changes in quantitative variables to predict treatment response under ILP. Histopathologic results after subsequent tumor resection served as the reference standard, and patients were categorized as responders or nonresponders on the basis of the 6-stage regression scale by Salzer-Kuntschik. Results: Histopathologic analysis categorized 27 patients as responders (grades I-III) and 18 patients as nonresponders (grades IV-VI). Calculated sensitivity, specificity, positive and negative predictive values, and diagnostic accuracy were 22%, 89%, 75%, 43%, and 49% for RECIST; 70%, 44%, 66%, 50%, and 60% for the Choi criteria; and 85%, 78%, 85%, 78%, and 82% for PERCIST. Receiver-operating-characteristic analysis revealed an area under the curve (AUC) of 0.56 for RECIST, 0.57 for the Choi criteria, and 0.82 for PERCIST. The combined regression model revealed higher values (AUC, 0.90) than for the stand-alone analysis, however, differences to metabolic parameters did not reach significance (P value: 0.067). Conclusion: Our study demonstrates the superiority of 18F-FDG PET over MRI data sets for response assessment of STS under neoadjuvant ILP. In a clinical setting, MRI delivers valuable information for presurgical assessment. Therefore, combining 18F-FDG PET and MRI data may enable more reliable treatment planning and therapy monitoring of STS.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Grueneisen J, Schaarschmidt B, Demircioglu A, et al. 18F-FDG PET/MRI for Therapy Response Assessment of Isolated Limb Perfusion in Patients with Soft-Tissue Sarcomas. J Nucl Med. 2019. PMID: 30926647. doi:10.2967/jnumed.119.226761

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。